Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination
During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From De...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/1/12 |
| _version_ | 1797339376875732992 |
|---|---|
| author | Matthaios Speletas Ioanna Voulgaridi Zacharoula Bogogiannidou Styliani Sarrou Maria A. Kyritsi Aikaterini Theodoridou Katerina Dadouli Alexia Matziri Alexandros Vontas Dimitra Pappa Adamos-Konstantinos Konstantinou Christina Tsigalou Fani Kalala Varvara A. Mouchtouri Christos Hadjichristodoulou |
| author_facet | Matthaios Speletas Ioanna Voulgaridi Zacharoula Bogogiannidou Styliani Sarrou Maria A. Kyritsi Aikaterini Theodoridou Katerina Dadouli Alexia Matziri Alexandros Vontas Dimitra Pappa Adamos-Konstantinos Konstantinou Christina Tsigalou Fani Kalala Varvara A. Mouchtouri Christos Hadjichristodoulou |
| author_sort | Matthaios Speletas |
| collection | DOAJ |
| description | During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (<i>p</i> = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease. |
| first_indexed | 2024-03-08T09:45:08Z |
| format | Article |
| id | doaj.art-e9cf798e6ccf436fabf548fd513026e3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-08T09:45:08Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e9cf798e6ccf436fabf548fd513026e32024-01-29T14:25:12ZengMDPI AGVaccines2076-393X2023-12-011211210.3390/vaccines12010012Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 VaccinationMatthaios Speletas0Ioanna Voulgaridi1Zacharoula Bogogiannidou2Styliani Sarrou3Maria A. Kyritsi4Aikaterini Theodoridou5Katerina Dadouli6Alexia Matziri7Alexandros Vontas8Dimitra Pappa9Adamos-Konstantinos Konstantinou10Christina Tsigalou11Fani Kalala12Varvara A. Mouchtouri13Christos Hadjichristodoulou14Department of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceDepartment of Pathology, Faculty of Medicine, University Hospital of Larissa, 41500 Larissa, GreecePsychogeriatric Hospital “Ippokrateio Therapeutirio”, 40011 Larissa, GreeceLaboratory of Hygiene and Environmental Protection, Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, GreeceDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, GreeceDuring the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (<i>p</i> = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease.https://www.mdpi.com/2076-393X/12/1/12booster vaccinationCOVID-19 mRNA vaccinationanti-SARS-CoV-2 IgA responsesanti-SARS-CoV-2 IgG responsesSARS-CoV-2 |
| spellingShingle | Matthaios Speletas Ioanna Voulgaridi Zacharoula Bogogiannidou Styliani Sarrou Maria A. Kyritsi Aikaterini Theodoridou Katerina Dadouli Alexia Matziri Alexandros Vontas Dimitra Pappa Adamos-Konstantinos Konstantinou Christina Tsigalou Fani Kalala Varvara A. Mouchtouri Christos Hadjichristodoulou Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination Vaccines booster vaccination COVID-19 mRNA vaccination anti-SARS-CoV-2 IgA responses anti-SARS-CoV-2 IgG responses SARS-CoV-2 |
| title | Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| title_full | Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| title_fullStr | Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| title_full_unstemmed | Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| title_short | Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| title_sort | dynamics of anti sars cov 2 iga and igg responses and their protective effect against fatal disease after booster covid 19 vaccination |
| topic | booster vaccination COVID-19 mRNA vaccination anti-SARS-CoV-2 IgA responses anti-SARS-CoV-2 IgG responses SARS-CoV-2 |
| url | https://www.mdpi.com/2076-393X/12/1/12 |
| work_keys_str_mv | AT matthaiosspeletas dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT ioannavoulgaridi dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT zacharoulabogogiannidou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT stylianisarrou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT mariaakyritsi dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT aikaterinitheodoridou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT katerinadadouli dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT alexiamatziri dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT alexandrosvontas dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT dimitrapappa dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT adamoskonstantinoskonstantinou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT christinatsigalou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT fanikalala dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT varvaraamouchtouri dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination AT christoshadjichristodoulou dynamicsofantisarscov2igaandiggresponsesandtheirprotectiveeffectagainstfataldiseaseafterboostercovid19vaccination |